Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 345 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Attention Control Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Top-Down Executive Control in Traumatic Brain Injury (TBI), PTSD and Combined

NCT01072006
View directory record Official record
Conditions
PTSD, TBI (Traumatic Brain Injury)
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of Danicopan in Healthy Adults

NCT05016206
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640185
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01124708
View directory record Official record
Conditions
ADHD
Interventions
TC-5619-238, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
16
States / cities
Bradenton, Florida • Jacksonville, Florida • Lauderhill, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT05428033
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsule, placebo capsule
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02808104
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
mazindol
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Newport Beach, California • Jacksonville, Florida • Marshfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Assessing Mobile Apps for Adult ADHD

NCT06256003
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
UC-A, UC-N
Device
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Terminated Not applicable Interventional

Pharmacogenomics for Improving Pediatric ADHD Treatment

NCT03730870
View directory record Official record
Conditions
Attention Deficit Disorders With Hyperactivity
Interventions
Pharmacogenomics report
Diagnostic Test
Lead sponsor
Clinical and Translational Genome Research Institute, Inc.
Other
Eligibility
6 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hamilton, New Jersey • Mountainside, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns

NCT07189754
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognitive Dysfunction, Cognitive Disorder, Memory Problems
Interventions
Sabroxy™ (Oroxylum indicum extract), Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
60 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

NCT02253745
View directory record Official record
Conditions
ADHD
Interventions
V81444, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 21, 2026, 11:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Mediodorsal Thalamus Representations Underlying Human Cognitive Flexibility

NCT07217652
View directory record Official record
Conditions
Schizophrenia, Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions
High-resolution fMRI during working memory, cognitive control, and decision-making tasks
Other
Lead sponsor
Kai Hwang
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational

Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants

NCT01310439
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Hartford Hospital
Other
Eligibility
13 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Jul 21, 2026, 11:16 AM EDT
Not yet recruiting No phase listed Observational

Role of Theta Frequency Oscillations in Proactive and Reactive Control Processes in Youth With Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD)

NCT07566468
View directory record Official record
Conditions
ADHD, Obsessive Compulsive Disorder (OCD), Healthy Volunteer
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, atomoxetine, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
6 Years to 12 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT03442764
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

NCT00997984
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

NCT05008549
View directory record Official record
Conditions
Attention, Mood
Interventions
Cranberry Juice Product
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of SPD465 in Adults With ADHD

NCT00202605
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Little Rock, Arkansas • Irvine, California • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Not applicable Interventional

Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02257216
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Vayarin®, Placebo
Other
Lead sponsor
Enzymotec
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Marietta, Georgia • Mount Kisco, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02466425
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Dothan, Alabama • Orange, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 4 Interventional

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

NCT00323947
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions
Extended Release Methylphenidate (OROS-Methylphenidate)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jul 21, 2026, 11:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adolescent Changes in Brain and Behavior in Boys and Girls With ADHD

NCT05927506
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Other
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 2 Interventional Results available

Ganaxolone Treatment in Children With Fragile X Syndrome

NCT01725152
View directory record Official record
Conditions
Fragile x Syndrome
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 21, 2026, 11:16 AM EDT
Completed Phase 4 Interventional Results available

CONCERTA Lab School Study

NCT00799487
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CONCERTA (methylphenidate HCl) or placebo
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
9 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Little Rock, Arkansas • Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jul 21, 2026, 11:16 AM EDT